SCHEMBL6604919

SCHEMBL6604919

CC(C)(C)OC(=O)Nc1cnccc1C=O.CN(C)Cc1ccncc1NC(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 3/20 0.38
NAMPT P43490 2/20 0.35
ATR Q13535 1/20 0.34
RAB9A P51151 1/20 0.34
CCNE2 O96020 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
GSK3B P49841 1/20 0.33
AAK1 Q2M2I8 1/20 0.33
IDO1 P14902 1/20 0.32
LATS1 O95835 1/20 0.32
LATS2 Q9NRM7 1/20 0.32
BRD9 Q9H8M2 1/20 0.32
MAP4K1 Q92918 1/20 0.32
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
BRD4 O60885 1/20 0.31
PDE5A O76074 1/20 0.31
PDE4A P27815 1/20 0.31
PDE1A P54750 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6034950 0.87 CYP17A1 (0.44) CYP17A1NAMPTATRRAB9ACCNE2
SCHEMBL1020140 0.84 CYP17A1 (0.47) CYP17A1NAMPTATRRAB9AIDO1
SCHEMBL29957148 0.84 CYP17A1 (0.47) CYP17A1NAMPTATRRAB9AIDO1
SCHEMBL6604921 0.82 CYP17A1 (0.32) CYP17A1RAB9ACCNE2CCNE1CDK2
SCHEMBL6035358 0.80 CCNE2 (0.42) CCNE2CCNE1CDK2GSK3BSLC6A2
SCHEMBL12018154 0.78 CYP17A1 (0.48) CYP17A1NAMPTATRRAB9ALATS1
SCHEMBL30601022 0.78 CYP17A1 (0.48) CYP17A1NAMPTATRRAB9ALATS1
SCHEMBL3824156 0.75 KDM4C (0.42)
SCHEMBL3537539 0.75 NAMPT (0.42) CYP17A1NAMPTATRRAB9ABRD9
SCHEMBL3537542 0.75 NAMPT (0.42) CYP17A1NAMPTATRRAB9ABRD9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1414801-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 AstraZeneca AB (SE) 2004-05-06 EP disclosed
WO-2003004472-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 ASTRAZENECA AB (SE) 2003-01-16 WO disclosed